Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
THX PharmaSTU:3VG +5.09%39 3-1 Month Momentum % is 5.73% as of Aug. 09, 2026. GuruFocus rates STU:3VG with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 1,384 Biotechnology companies, THX Pharma ranks better than 67.56% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-09), THX Pharma's 3-1 Month Momentum % is 5.73%.
The industry rank for THX Pharma's 3-1 Month Momentum % or its related term are showing as below:
STU:3VG's 3-1 Month Momentum % is ranked better than 67.56% of 1384
companies
in the Biotechnology industry
Industry Median: -7.155
vs STU:3VG: 5.73
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
THX Pharma 3-1 Month Momentum % Related Terms
STU:3VG vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, THX Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
THX Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, THX Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where THX Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THX Pharma (STU:3VG) has a 3-1 Month Momentum % of 5.73% as of Aug. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #449 out of 1384 companies in the Biotechnology industry, placing it in the top 32.4%.
Is THX Pharma's 3-1 Month Momentum % too high?
THX Pharma's current 3-1 Month Momentum % is 5.73%. Based on the distribution chart, THX Pharma ranks #449 out of 1384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, THX Pharma has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #449 out of 1384 companies for 3-1 Month Momentum %. This puts THX Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on THX Pharma and its competitors. THX Pharma's current 3-1 Month Momentum % is 5.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current 3-1 Month Momentum % of 5.73%. The current 3-1 Month Momentum % is 5.73%. THX Pharma's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current 3-1 Month Momentum % is 5.73% as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
39GF Score
Get the complete analysis for STU:3VG
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3VG has been successfully added to your 
